Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | CRHBP | P24387 | 2/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.51 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 3/20 | 0.48 |
| ▸ | MMP13 | P45452 | 3/20 | 0.48 |
| ▸ | MMP9 | P14780 | 2/20 | 0.48 |
| ▸ | MMP14 | P50281 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL492003 | 0.99 | ALDH1A1 (0.53) | ALDH1A1LMNAGAASMN1; SMN2MAPK1 | |
| SCHEMBL6079459 | 0.97 | ALDH1A1 (0.58) | ALDH1A1LMNAGAASMN1; SMN2MAPK1 | |
| SCHEMBL6078369 | 0.97 | ALDH1A1 (0.58) | ALDH1A1LMNAGAASMN1; SMN2MAPK1 | |
| SCHEMBL6382811 | 0.97 | ALDH1A1 (0.58) | ALDH1A1LMNAGAASMN1; SMN2MAPK1 | |
| SCHEMBL6079023 | 0.97 | ALDH1A1 (0.58) | ALDH1A1LMNAGAASMN1; SMN2MAPK1 | |
| SCHEMBL372609 | 0.96 | ALDH1A1 (0.56) | ALDH1A1LMNAGAASMN1; SMN2MAPK1 | |
| SCHEMBL492001 | 0.89 | HSP90AA1 (0.55) | ALDH1A1LMNAGAASMN1; SMN2MAPK1 | |
| SCHEMBL6078074 | 0.87 | ALDH1A1 (0.51) | ALDH1A1LMNAGAASMN1; SMN2MAPK1 | |
| SCHEMBL6078078 | 0.87 | ALDH1A1 (0.51) | ALDH1A1LMNAGAASMN1; SMN2MAPK1 | |
| SCHEMBL6078081 | 0.87 | ALDH1A1 (0.51) | ALDH1A1LMNAGAASMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541410-B2 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2408756-B1 | ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2013-05-15 | — | — | EP | disclosed |
| US-20120108573-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2012-05-03 | — | — | US | disclosed |
| US-8106213-B2 | For example, 2-(4-chloro-phenylsulfonylamino)-4,5-dimethoxy-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide; for therapy and prophylaxis of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| EP-2408756-A1 | ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES | Bristol-Myers Squibb Company (US) | 2012-01-25 | — | — | EP | disclosed |
| US-7977362-B2 | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-12 | — | — | US | disclosed |
| WO-2010108067-A1 | ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | disclosed |
| US-20100240708-A1 | Alpha-(N-Benzenesulfonamido)Cycloalkyl Derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-23 | — | — | US | disclosed |
| US-20080096936-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | TELEVOX SOFTWARE, INCORPORATED | 2008-04-24 | — | — | US | disclosed |
| US-7326789-B2 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-05 | — | — | US | disclosed |
| CN-1332943-C | Sulfur-substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMACEUTICALS AG (DE) | 2007-08-22 | — | — | CN | disclosed |
| EP-1614678-A2 | Sulfur substituted sulfonylaminocarboxylic acid N-heteroarylamides, their preparation, their use and pharmaceutical preparations comprising them | Sanofi-Aventis Deutschland GmbH (DE) | 2006-01-11 | — | — | EP | disclosed |
| US-6881735-B2 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-19 | — | — | US | disclosed |
| US-20040186145-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2004-09-23 | — | — | US | disclosed |
| US-20020061887-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2002-05-23 | — | — | US | disclosed |
| US-6335334-B1 | HYPERTENSIVE AGENTS, ANTICOAGULANTS; CARDIOVASCULAR AND SEXUAL DISORDERS, ANGINA PECTORIS, AND ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-01 | — | — | US | disclosed |
| CN-1308606-A | Sulfur-substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMACEUTICALS AG (DE) | 2001-08-15 | — | — | CN | disclosed |
| EP-1095016-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000002851-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240708-A1 | Alpha-(N-Benzenesulfonamido)Cycloalkyl Derivatives | BACE1, BACE2, APP | ALDH1A1 1454/4885LMNA 449/4885GAA 17/4885 |
| US-20120108573-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | GUCY1A1, GUCY1B1, GUCY1A2 | ALDH1A1 457/4885LMNA 446/4885GAA 1042/4885 |
| US-20040186145-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | GUCY1A1, GUCY1B1, GUCY1A2 | ALDH1A1 860/4885LMNA 676/4885GAA 1212/4885 |
| US-20020061887-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | GUCY1A1, GUCY1B1, GUCY1A2 | ALDH1A1 860/4885LMNA 676/4885GAA 1212/4885 |
| US-20080096936-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | GUCY1A1, GUCY1A2, GUCY1B1 | ALDH1A1 391/4885LMNA 580/4885GAA 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.